Aleksandra Kozic

Dr. Aleksandra Kozic

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2025 in Cancer Medicine
Verified
Journal Article
Open access
SSSonja Salinger
Sonja Salinger
AKAleksandra Kozic
Aleksandra Kozic
BDBoris Dzudovic
Boris Dzudovic
BSBojana Subotic
Bojana Subotic
JMJovan Matijasevic
Jovan Matijasevic
SOSlobodan Obradovic
Slobodan Obradovic
Background: Newly or already diagnosed cancer might significantly influence the clinical presentation, outcome, and therapy of acute pulmonary embolism (PE). Methods: Out of 1745 patients with acute PE, 66 patients were diagnosed with cancer during an initial hospitalization due to acute PE (where PE was the first clinical manifestation of cancer), 165 patients had known cancer treated in the last 6 months, and 1514 patients had acute PE without known or suspected cancer. The primary end‐point of the present study was all‐cause hospital death. The secondary end‐points were the proportion of patients treated with thrombolysis and who had severe disease, and the ocurrence of major or clinically relevant nonmajor bleeding. Results: Patients with PE as the first presentation of cancer had the highest hospital mortality rate compared to the other two groups (HR for the mortality rate in patients without cancer as a reference, adjusted to four‐stratum mortality risk, and Charlson's comorbidity index was 3.440; 95% confidence interval (CI), 1.795–6.591; p < 0.001). Patients with known cancer before PE had a significantly lower chance of being treated with thrombolysis than patients without cancer (OR, 0.523; 95% CI, 0.339–0.807; p = 0.003); additionally, this difference was attenuated but remained when the OR was adjusted to age (OR, 0.542; 95% CI, 0.351–0.838; p = 0.006). Patients with known cancer had a higher frequency of high‐risk PE compared with patients without cancer (18.2% vs. 12.8%; p < 0.001). Patients with PE as the first manifestation of cancer had a higher frequency of intermediate‐high‐risk PE than those without (36.4% vs. 30.9%; p < 0.001). There was no significant difference in bleeding during hospitalization between groups. Conclusion: Patients with cancer had a more severe presentation of acute PE than patients without. Furthermore, patients with PE as the first manifestation of cancer had the highest hospital mortality rate, and patients with known cancer were least likely to be treated with thrombolysis.

13 January 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
DIDejan Ilić
Dejan Ilić
ZJZoran Jovic
Zoran Jovic
ZMZorica Mladenovic
Zorica Mladenovic
VPVesna Pejovic
Vesna Pejovic
BLBranislava Lung
Branislava Lung
SOSlobodan Obradovic
Slobodan Obradovic
Background/Objectives: It is unknown how early exercise therapy combined with acupuncture (AP) affects the speed of recovery in patients suffering from heart failure with reduced ejection fraction (HFrEF) who are hospitalized due to worsening HF. Methods: A prospective, sham-procedure-controlled, double-blind, randomized clinical trial with three patient groups was conducted. The study included patients with HFrEF who were hospitalized for worsening HF. After initial stabilization, patients were randomly assigned to three groups, the controls (C) treated with optimal drug therapy (ODT); E1 received ODT with kinesitherapy, and sham AP; E2 received ODT, kinesitherapy, and needle AP aiming to enhance compensation. Improvement in physical activity was measured by the modified Barthel index (A test), 2 or 6 min walking tests, an endurance walking test, and decrease of blood brain natriuretic peptide (BNP). Results: A total of 120 patients completed the study. The average age was 74 years, 73.3% were male, median EF was 32%, and 83.3% were New York Heart Association (NYHA) Class III. After the fifth day of therapy, the E2 group showed the greatest improvement in the A test compared to other groups (p = 0.022). After 5 days, 80%, 50%, and 10% achieved an A test score of 30 or higher, demonstrating functional independence, (p < 0.01) in the E2, E1, and C groups, respectively. At hospital discharge, the E2 group showed significantly better walking endurance compared to the E1 and C groups (p < 0.001). At discharge, BNP decreased significantly more in both E groups, compared to the C group. Conclusions: Short-term early rehabilitation with AP and kinesitherapy significantly improves the functional status of HFrEF decompensated patients when compared to kinesitherapy alone and ODT.

23 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
DIDejan Ilić
Dejan Ilić
ZJZoran Jovic
Zoran Jovic
ZMZorica Mladenovic
Zorica Mladenovic
VPVesna Pejovic
Vesna Pejovic
BLBranislava Lung
Branislava Lung
SOSlobodan Obradovic
Slobodan Obradovic
Background/Objectives: It is unknown how early exercise therapy combined with acupuncture (AP) affects the speed of recovery in patients with heart failure with reduced ejection fraction (HFrEF) who are hospitalized due to worsening HF. Methods: A prospective, sham-procedure-controlled, double-blind, randomized clinical trial with three patient groups was conducted. The study included patients with HFrEF who were hospitalized for worsening HF. After initial stabilization, patients were randomly assigned to three groups, the controls (C) treated with optimal drug therapy (ODT); E1 received ODT with kinesitherapy, and sham AP; E2 received ODT, kinesitherapy, and needle AP aiming to enhance compensation. Improvement in physical activity was measured by the modified Barthel index (A test), 2- or 6-minute, and endurance walking tests, and decrease of blood brain natriuretic peptide (BNP). Results: The 120 patients completed the study. The average age was 74 years, males 73.3%, median EF 32%, NYHA III had 83.3%. After the 5th day of therapy, the E2 group showed the greatest improvement in the A test compared to other groups (p=0.022). After 5 days, 80%, 50% and 10% achieved A test score of 30 or higher, demonstrating functional independence (p<0.01) in E2, E1 and C group, respectively. At hospital discharge, the E2 group showed significantly better walking endurance compared to the E1 and C groups (p<0.001). At discharge, BNP significantly decreased in both E groups. Conclusions: Short-term early rehabilitation with AP and kinesitherapy significantly improves the functional status of HFrEF decompensated patients when compared to kinesitherapy alone and ODT.

5 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SSSonja S Salinger
Sonja S Salinger
AKAleksandra Kozic
Aleksandra Kozic
SIStefan Ilić
Stefan Ilić
BDBoris Dzudovic
Boris Dzudovic
BSBojana Subotic
Bojana Subotic
SOSlobodan Obradovic
Slobodan Obradovic
Background/Objectives: Acute pulmonary embolism (PE) is a major cause of cardio-vascular mortality, with prognosis influenced by hemodynamic status, comorbidities, and biomarker profiles. Although several laboratory markers have demonstrated prog-nostic relevance in PE, it remains unclear whether their predictive performance differs in patients with active malignancy. This study aimed to identify laboratory predictors of in-hospital mortality in acute PE and to evaluate the modifying effect of malignancy on biomarker-based prognostic stratification. Methods: This retrospective multicenter cohort study included 2803 consecutive patients with computed tomography-confirmed acute PE enrolled in the Regional Pulmonary Embolism Registry (REPER) between January 2015 and April 2026. Univariate and multivariable logistic regression analyses were performed to identify predictors of in-hospital mortality in the overall cohort and in subgroups stratified by malignancy status. Interaction analyses were used to assess effect modification by malignancy. Results: Active malignancy was present in 14.02% of patients, while overall in-hospital mortality was 14.93%. In the overall cohort, multivariable analysis identified malignancy (OR 1.698, 95% CI 1.128–2.555, p = 0.011), C-reactive protein (CRP), glucose, creatinine clearance (CrCl), platelet count, and white blood cell count as independent predictors of in-hospital mortality (BNP was excluded from multivariable models due to missing data). Mortality was significantly higher in patients with ma-lignancy compared with those without (20.9% vs. 13.2%, p < 0.001). In patients with malignancy, CRP and glucose remained independent predictors, whereas in non-malignant patients, CRP, glucose, and CrCl were independently associated with mortality. Significant interaction effects were observed for CrCl, age, glucose, and white blood cell count. Conclusions: Malignancy is an important predictor of in-hospital mortality in acute PE and may partially influence the prognostic performance of certain conventional biomarkers. These findings suggest that while standard risk markers remain broadly reliable, specific parameters might benefit from a cautious, malignancy-aware interpretation.

7 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
SSSonja S Salinger
Sonja S Salinger
AKAleksandra Kozic
Aleksandra Kozic
SIStefan Ilić
Stefan Ilić
BDBoris Dzudovic
Boris Dzudovic
BSBojana Subotic
Bojana Subotic
SOSlobodan Obradovic
Slobodan Obradovic
Background/Objectives: Acute pulmonary embolism (PE) is a major cause of cardiovascular mortality, with prognosis influenced by hemodynamic status, comorbidities, and biomarker profiles. Although several laboratory markers have demonstrated prognostic relevance in PE, it remains unclear whether their predictive performance differs in patients with active malignancy. This study aimed to identify laboratory predictors of in-hospital mortality in acute PE and evaluate the modifying effect of malignancy on biomarker-based prognostic stratification. Methods: This retrospective multicenter cohort study included 2803 consecutive patients with confirmed acute PE enrolled in the Regional Pulmonary Embolism Registry (REPER) between January 2015 and April 2026. Univariate and multivariable logistic regression analyses were performed to identify predictors of in-hospital mortality in the overall cohort and subgroups stratified by malignancy status. Interaction analyses were used to formally assess effect modification by malignancy. Results: Active malignancy was present in 14.02% of patients, and overall in-hospital mortality was 11.10%. Multivariable analysis identified malignancy, CRP, glucose, creatinine clearance (CrCl), platelet count, and ESC risk category as independent predictors of in-hospital mortality. In-hospital mortality was significantly higher in patients with malignancy compared with those without (16.54% vs. 10.21%, p < 0.001). In the malignant subgroup, CRP and glucose remained independent predictors, whereas in non-malignant patients, CRP, glucose, CrCl, and ESC risk category were independently associated with outcome. Significant interactions between malignancy status and CrCl, age, glucose, and total leukocyte count suggest that the prognostic contribution of these variables may differ according to cancer status. Conclusions: Active malignancy is an independent predictor of in-hospital mortality in acute PE and appears to be associated with a more severe presentation. Our findings suggest that malignancy may also modify the prognostic performance of certain biomarkers. These observations suggest that conventional risk stratification tools may require cautious, malignancy-aware interpretation and that prospective studies validating malignancy-adapted prognostic frameworks are warranted.

24 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
AKAleksandra Kozic
Aleksandra Kozic
SSSonja S Salinger
Sonja S Salinger
BDBoris Dzudovic
Boris Dzudovic
JMJovan Matijasevic
Jovan Matijasevic
MBMarija Benic
Marija Benic
SOSlobodan Obradovic
Slobodan Obradovic
Background/Objectives: Pulmonary embolism (PE) may represent the first clinical manifestation of a previously unrecognized malignancy. We aimed to develop the OncoScore, a diagnostic prediction score for estimating the probability of previously unrecognized malignancy being diagnosed during the index hospitalization for acute PE. Methods: We conducted a retrospective diagnostic prediction model derivation study using prospectively collected data from the multicenter Regional Pulmonary Embolism Registry (REPER). Candidate predictors were assessed using logistic regression and Chi-square Automatic Interaction Detection (CHAID) analysis, and independent predictors were incorporated into the OncoScore. Discrimination was assessed by receiver operating characteristic (ROC) analysis, calibration by calibration slope and a calibration plot, and internal validation by bootstrap resampling. Diagnostic performance measures were calculated using the cut-off value determined by the Youden index. Results: Among 2615 patients with acute PE, 91 had newly diagnosed malignancy, 265 had previously known malignancy, and 2259 had no malignancy. The final OncoScore included hemoglobin, C-reactive protein, platelet count, and leukocyte count, with a total score ranging from 0 to 7 points. The OncoScore yielded an area under the curve (AUC) of 0.702 (95% confidence interval [CI] 0.653–0.751; p < 0.001). Bootstrap internal validation of the fixed score yielded an optimism-corrected AUC of 0.7013 and an optimism-corrected calibration slope of 1.015. When predictor selection and CHAID cut-point determination were repeated within the bootstrap procedure, the optimism-corrected AUC was 0.6560. Patients were stratified as low (≤2), intermediate (3–4), and high risk (≥5), with observed malignancy prevalences of 1.1%, 5.5%, and 10.8%, respectively. At a cut-off of ≥3 points, sensitivity was 87.5%, specificity 46.5%, positive predictive value 6.4%, and negative predictive value 98.9%. Conclusions: The OncoScore is a simple laboratory-based prediction tool that showed moderate discrimination and identified clinically distinct risk strata for malignancy diagnosed during the index hospitalization for acute PE. The score should be considered a preliminary derivation-stage model, and independent external validation is required before clinical implementation.